Biotech & Life Sciences
-
China’s Hemophilia A Gene Therapy Partnership That Could Change Everything
Imagine living with a condition where your blood cannot clot properly. Every bump, every minor injury, every joint movement carries the risk of a bleeding episode that could cause permanent damage. For people with severe hemophilia A, that is daily reality. The current standard of care requires regular injections of clotting factor, sometimes every few
-
Function Health Connects Your Lab Results to AI — Here’s Why It Matters
Your blood test results just got a lot more useful — if you know how to use them Most people who get lab work done receive a PDF, glance at the numbers, and have no idea what half of them mean. Function Health is trying to change that. On March 20, 2026, the Austin-based health
-
GI Innovation and J&J Team Up to Tackle Advanced Prostate Cancer
A small Korean biotech just secured a deal with Johnson & Johnson to tackle one of prostate cancer’s hardest challenges When a company the size of Johnson & Johnson agrees to supply its drug to a clinical trial run by a smaller biotech, it is not a routine transaction. It is a vote of confidence.
-
How OPTEL Is Reshaping Pharmaceutical Manufacturing
Pharma factories are leaving capacity on the table — and this AI partnership wants to fix that Two Canadian companies just announced a partnership that could change how pharmaceutical manufacturers plan their production. On March 17, 2026, OPTEL and Kaster Technologies revealed a commercial agreement to bring AI-powered production planning to drug manufacturers worldwide. The
-
Why PureHealth Research Focuses on the Liver-Lymph Axis
PureHealth Research Targets the Liver-Lymphatic Connection to Optimize Systemic Detoxification On March 14, 2026, Virginia-based PureHealth Research announced a strategic expansion of its wellness portfolio, focusing on the biological synergy between the liver and the lymphatic system. Moving away from traditional isolated-organ health models, the company is pioneering a systemic approach that addresses how metabolic
-
Small Molecules, Big Data: The AI-Powered Future of Oral Obesity Therapies
PRISM BioLab and Receptor.AI Partner to Navigate the Undruggable PPI Landscape On March 12, 2026, Tokyo-based PRISM BioLab and U.S.-based TechBio firm Receptor.AI announced a strategic collaboration to build an integrated, AI-navigated drug discovery platform. This partnership aims to solve one of the most persistent challenges in pharmacology: the discovery of orally available small molecules
-
16 Billion in Growth? Inside the Rapid Rise of Wire-Free Coronary Physiology
Large-Scale Medicare Study Validates CathWorks FFRangio Outcomes Through Two Years At the Cardiovascular Research Technologies (CRT) 2026 conference in Washington, D.C., researchers presented the first-ever United States Medicare data comparing angiography-derived physiology (ADP) to traditional invasive methods. The study, led by Dr. Christopher Chieh Yang Koo and investigators from Harvard Medical School, analyzed over 4,000
-
SkinCure Oncology Sues Federal Government: The Fight for “Scalpel-Free” Cancer Care
SkinCure Oncology, the provider of a popular nonsurgical skin cancer treatment known as Image-Guided SRT, announced on March 6, 2026, that it has filed a lawsuit in federal court. The company is seeking an emergency injunction to stop new Medicare policies that would significantly limit patient access to this technology. The lawsuit specifically names the
-
Can You Drink Your Way to Better Skin? Vital Proteins Debuts New Collagen Water
Transforming Daily Hydration with Science-Backed Bioactive Peptides Vital Proteins, the industry leader in collagen supplementation, officially debuted its latest innovation on March 4, 2026: Vital Proteins Collagen Sparkling Water. This launch represents a strategic pivot into the high-growth ready-to-drink (RTD) functional beverage space; it offers consumers a “beauty-from-within” solution in a convenient, carbonated format. The
-
Going Private: Consortium to Acquire Select Medical in $3.9 Billion Cash Deal
The healthcare sector just saw a massive consolidation move from the inside out. On March 2, 2026, Select Medical Holdings Corporation (NYSE: SEM) announced it’s being taken private in a $3.9 billion deal. The architect of the move? A consortium led by the company’s own Executive Chairman and Co-Founder, Robert A. Ortenzio, Senior EVP Martin
